Short term tapering of Ruxolitinib prior conditioning therapy with allogeneic stem cell transplantation for primary myelofibrosis
Not Applicable
- Conditions
- Primary myelofibrosis
- Registration Number
- JPRN-UMIN000019421
- Lead Sponsor
- Department of Internal Medicine, Hakodate Municipal Hospital, Hakodate, Japan
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 2
Inclusion Criteria
Not provided
Exclusion Criteria
1.Positive of HBs antigen, HCV antibody, HIV antibody or HTLV-1 antibody 2.Uncontrollable psychiatric symptom 3.Pregnant woman or lactating 4.Active other cancers 5.Uncontrollable active infection 6.Hepatic cirrhosis 7.More than BMI 35 8.Others
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1.Engraftment and survival at 4 weeks after allo-SCT 2.Analysis of cytokine and growth factor during Allo-SCt
- Secondary Outcome Measures
Name Time Method 1.Survival at 12 weeks after allo-SCT 2.Disease status at 4 and 12 weeks after Allo-SCT 3.Acute GVHD 4.Infection 5.Adverse event (CTCAE ver.4 Grade3 or more) 6.Analysis of lymphocyte subsets and immunoglobulin at 4, 8 and 12 weeks after allo-SCT